Seres Therapeutics (MCRB) Asset Writedowns and Impairment (2024 - 2026)
Seres Therapeutics (MCRB) posted Asset Writedowns and Impairment of $3.3 million for Q1 2024.
Seres Therapeutics (MCRB) Asset Writedowns and Impairment (2024 - 2026) Analysis & Trends
Seres Therapeutics has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $3.3 million in Q1 2024.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $3.3 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $3.3 million (changed N/A YoY) and the FY2024 annual result came in at $3.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment steadied at $3.3 million in Q1 2024 per MCRB's latest filing.
- Over five years, Asset Writedowns and Impairment peaked at $3.3 million in Q1 2024 and troughed at $3.3 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.81 Mn |
| Jun 30, 2026 | 5.81 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |